Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Background. Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. Methods. A retrospective medical record review was conducted in 200 RRMM patients in Fran...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2019/4625787 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555957724381184 |
|---|---|
| author | Huamao Mark Lin Keith L. Davis James A. Kaye Katarina Luptakova Saurabh P. Nagar Mohamad Mohty |
| author_facet | Huamao Mark Lin Keith L. Davis James A. Kaye Katarina Luptakova Saurabh P. Nagar Mohamad Mohty |
| author_sort | Huamao Mark Lin |
| collection | DOAJ |
| description | Background. Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. Methods. A retrospective medical record review was conducted in 200 RRMM patients in France. From first relapse, patients were assessed on second-/third-line treatments, progression-free survival (PFS), overall survival (OS), and healthcare utilization. Results. Fifty-five high risk and 113 standard risk patients were identified. Overall, 192 patients (96%) received second-line therapy after relapse. Lenalidomide-based regimens were most common (>50%) in second line. Hospitalization incidence in high risk patients was approximately twice that of standard risk patients. From Kaplan-Meier estimation, median (95% CI) second-line PFS was 21.4 (17.5, 25.0) months (by high versus standard risk: 10.6 [6.4, 17.0] versus 28.7 [22.1, 37.3] months). Among second-line recipients, 47.4% were deceased at data collection. Median second-line OS was 59.4 (38.8, NE) months (by high versus standard risk: 36.5 [17.4, 50.6] versus 73.6 [66.5, NE] months). Conclusions. The prognostic importance of cytogenetic risk in RRMM was apparent, whereby high (versus standard) risk patients had decidedly shorter PFS and OS. Frequent hospitalizations indicated potentially high costs associated with RRMM, particularly for high risk patients. These findings may inform economic evaluations of RRMM therapies. |
| format | Article |
| id | doaj-art-d1602ce2e4904f4dab213fe183f4e6f9 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-d1602ce2e4904f4dab213fe183f4e6f92025-02-03T05:46:49ZengWileyAdvances in Hematology1687-91041687-91122019-01-01201910.1155/2019/46257874625787Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in FranceHuamao Mark Lin0Keith L. Davis1James A. Kaye2Katarina Luptakova3Saurabh P. Nagar4Mohamad Mohty5Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USARTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USARTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA 02452, USAMillennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USARTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USADepartment of Haematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, EBMT Paris Study Office, CEREST-TC, Saint-Antoine Hospital, Paris, FranceBackground. Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. Methods. A retrospective medical record review was conducted in 200 RRMM patients in France. From first relapse, patients were assessed on second-/third-line treatments, progression-free survival (PFS), overall survival (OS), and healthcare utilization. Results. Fifty-five high risk and 113 standard risk patients were identified. Overall, 192 patients (96%) received second-line therapy after relapse. Lenalidomide-based regimens were most common (>50%) in second line. Hospitalization incidence in high risk patients was approximately twice that of standard risk patients. From Kaplan-Meier estimation, median (95% CI) second-line PFS was 21.4 (17.5, 25.0) months (by high versus standard risk: 10.6 [6.4, 17.0] versus 28.7 [22.1, 37.3] months). Among second-line recipients, 47.4% were deceased at data collection. Median second-line OS was 59.4 (38.8, NE) months (by high versus standard risk: 36.5 [17.4, 50.6] versus 73.6 [66.5, NE] months). Conclusions. The prognostic importance of cytogenetic risk in RRMM was apparent, whereby high (versus standard) risk patients had decidedly shorter PFS and OS. Frequent hospitalizations indicated potentially high costs associated with RRMM, particularly for high risk patients. These findings may inform economic evaluations of RRMM therapies.http://dx.doi.org/10.1155/2019/4625787 |
| spellingShingle | Huamao Mark Lin Keith L. Davis James A. Kaye Katarina Luptakova Saurabh P. Nagar Mohamad Mohty Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France Advances in Hematology |
| title | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| title_full | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| title_fullStr | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| title_full_unstemmed | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| title_short | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| title_sort | real world treatment patterns outcomes and healthcare resource utilization in relapsed or refractory multiple myeloma evidence from a medical record review in france |
| url | http://dx.doi.org/10.1155/2019/4625787 |
| work_keys_str_mv | AT huamaomarklin realworldtreatmentpatternsoutcomesandhealthcareresourceutilizationinrelapsedorrefractorymultiplemyelomaevidencefromamedicalrecordreviewinfrance AT keithldavis realworldtreatmentpatternsoutcomesandhealthcareresourceutilizationinrelapsedorrefractorymultiplemyelomaevidencefromamedicalrecordreviewinfrance AT jamesakaye realworldtreatmentpatternsoutcomesandhealthcareresourceutilizationinrelapsedorrefractorymultiplemyelomaevidencefromamedicalrecordreviewinfrance AT katarinaluptakova realworldtreatmentpatternsoutcomesandhealthcareresourceutilizationinrelapsedorrefractorymultiplemyelomaevidencefromamedicalrecordreviewinfrance AT saurabhpnagar realworldtreatmentpatternsoutcomesandhealthcareresourceutilizationinrelapsedorrefractorymultiplemyelomaevidencefromamedicalrecordreviewinfrance AT mohamadmohty realworldtreatmentpatternsoutcomesandhealthcareresourceutilizationinrelapsedorrefractorymultiplemyelomaevidencefromamedicalrecordreviewinfrance |